238 related articles for article (PubMed ID: 18348680)
1. Neurotrophic factors as a therapeutic target for Parkinson's disease.
Evans JR; Barker RA
Expert Opin Ther Targets; 2008 Apr; 12(4):437-47. PubMed ID: 18348680
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease.
Voutilainen MH; Arumäe U; Airavaara M; Saarma M
FEBS Lett; 2015 Dec; 589(24 Pt A):3739-48. PubMed ID: 26450777
[TBL] [Abstract][Full Text] [Related]
3. Neurotrophic factor therapy for Parkinson's disease.
Rangasamy SB; Soderstrom K; Bakay RA; Kordower JH
Prog Brain Res; 2010; 184():237-64. PubMed ID: 20887879
[TBL] [Abstract][Full Text] [Related]
4. Neurotrophic factors hold promise for the future of Parkinson's disease treatment: is there a light at the end of the tunnel?
Nasrolahi A; Mahmoudi J; Akbarzadeh A; Karimipour M; Sadigh-Eteghad S; Salehi R; Farhoudi M
Rev Neurosci; 2018 Jul; 29(5):475-489. PubMed ID: 29305570
[TBL] [Abstract][Full Text] [Related]
5. Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy.
Domanskyi A; Saarma M; Airavaara M
Hum Gene Ther; 2015 Aug; 26(8):550-9. PubMed ID: 26176331
[TBL] [Abstract][Full Text] [Related]
6. Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson's disease: A systematic review and meta-analysis.
Hegarty SV; Lee DJ; O'Keeffe GW; Sullivan AM
Parkinsonism Relat Disord; 2017 May; 38():19-25. PubMed ID: 28215730
[TBL] [Abstract][Full Text] [Related]
7. Medium-throughput computer aided micro-island method to assay embryonic dopaminergic neuron cultures in vitro.
Planken A; Porokuokka LL; Hänninen AL; Tuominen RK; Andressoo JO
J Neurosci Methods; 2010 Dec; 194(1):122-31. PubMed ID: 20951734
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
Sun M; Kong L; Wang X; Lu XG; Gao Q; Geller AI
Brain Res; 2005 Aug; 1052(2):119-29. PubMed ID: 16018990
[TBL] [Abstract][Full Text] [Related]
9. Current disease modifying approaches to treat Parkinson's disease.
Lindholm D; Mäkelä J; Di Liberto V; Mudò G; Belluardo N; Eriksson O; Saarma M
Cell Mol Life Sci; 2016 Apr; 73(7):1365-79. PubMed ID: 26616211
[TBL] [Abstract][Full Text] [Related]
10. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
Garbayo E; Ansorena E; Blanco-Prieto MJ
Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the role of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
Kakoty V; Sarathlal KC; Kaur P; Wadhwa P; Vishwas S; Khan FR; Alhazmi AYM; Almasoudi HH; Gupta G; Chellappan DK; Paudel KR; Kumar D; Dua K; Singh SK
Neurol Sci; 2024 Apr; 45(4):1409-1418. PubMed ID: 38082050
[TBL] [Abstract][Full Text] [Related]
12. A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
Lapchak PA
Mov Disord; 1998; 13 Suppl 1():49-54. PubMed ID: 9613719
[TBL] [Abstract][Full Text] [Related]
13. Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson's Disease.
Tang T; Li Y; Jiao Q; Du X; Jiang H
Neurosci Bull; 2017 Oct; 33(5):568-575. PubMed ID: 28337696
[TBL] [Abstract][Full Text] [Related]
14. Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism.
Lindholm P; Saarma M
Mol Psychiatry; 2022 Mar; 27(3):1310-1321. PubMed ID: 34907395
[TBL] [Abstract][Full Text] [Related]
15. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.
Yasuhara T; Shingo T; Date I
Acta Med Okayama; 2007 Apr; 61(2):51-6. PubMed ID: 17471304
[TBL] [Abstract][Full Text] [Related]
16. Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review.
Staudt MD; Di Sebastiano AR; Xu H; Jog M; Schmid S; Foster P; Hebb MO
Gerontology; 2016; 62(3):371-80. PubMed ID: 26330171
[TBL] [Abstract][Full Text] [Related]
17. Role of Neurotrophic Factors in Parkinson's Disease.
Tome D; Fonseca CP; Campos FL; Baltazar G
Curr Pharm Des; 2017; 23(5):809-838. PubMed ID: 27928963
[TBL] [Abstract][Full Text] [Related]
18. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.
Whone AL; Boca M; Luz M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
J Parkinsons Dis; 2019; 9(2):301-313. PubMed ID: 30829619
[TBL] [Abstract][Full Text] [Related]
19. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
Lindvall O; Wahlberg LU
Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of nerve growth factors in Parkinson's disease.
Collier TJ; Sortwell CE
Drugs Aging; 1999 Apr; 14(4):261-87. PubMed ID: 10319241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
